MicroARN para la detección temprana de diabetes mellitus tipo 2revisión bibliográfica

  1. Martínez Altamirano, Joselyn Lissette 1
  2. Romo López, Ángel Geovanny 1
  1. 1 Universidad Técnica de Ambato, Facultad Ciencias de la Salud, Carrera de Medicina, Ambato, Ecuador
Journal:
Salud, Ciencia y Tecnología

ISSN: 2796-9711

Year of publication: 2023

Issue Title: Salud, Ciencia y Tecnología

Issue: 3

Pages: 507

Type: Article

DOI: 10.56294/SALUDCYT2023507 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Salud, Ciencia y Tecnología

Abstract

Introduction: Diabetes Mellitus (DM) is a glucose metabolism disorder of multiple etiology, representing more than 90% of diabetes cases around the world. Current studies have proposed microRNAs (miRNAs) as possible early biomarkers of the disease.Objective: review the literature on the use of miRNAs as biomarkers in the early detection of type 2 Diabetes Mellitus (T2DM). Methods: Comprehensive searches of scientific databases were carried out and nine studies that met the inclusion criteria were selected. These studies examined the expression profiles of specific miRNAs and their utility as diagnostic and prognostic markers. Results: They revealed that certain miRNAs, such as miR-21, miR-122, miR-148b-3p, miR-27a-3p and miR-135, showed significant changes in their expression in patients with T2DM and prediabetes compared to healthy individuals. These miRNAs were also associated with key metabolic processes, such as the regulation of insulin signaling, insulin resistance, and inflammation. Conclusions: These findings support the potential of miRNAs as biomarkers for early detection, prognosis, and management of T2DM and prediabetes. However, further research is required to validate and better understand the clinical relevance of miRNAs in these metabolic diseases.

Bibliographic References

  • Association AD. Standards of Care in Diabetes - 2023. Diabetes journals [Internet]. 2023;46(1):1–298. Available from: https://diabetesjournals.org/care
  • Webber S. International Diabetes Federation [Internet]. Vol. 102, Diabetes Research and Clinical Practice. 2021. 147–148 p. Available from: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
  • Vasu S, Kumano K, Darden CM, Rahman I, Lawrence MC, Naziruddin B. MicroRNA signatures as future biomarkers for diagnosis of diabetes states. Cells. 2019;8(12):1–32.
  • Wanken ZJ, Anderson PB, Bessen SY, Rode JB, Columbo JA, Trooboff SW, et al. The Profiling and Role of miRNAs in Diabetes Mellitus. J Hosp Med. 2020;72(1):286–92.
  • Jiménez-Lucena R, Camargo A, Alcalá-Diaz JF, Romero-Baldonado C, Luque RM, van Ommen B, et al. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. Exp Mol Med [Internet]. 2018;50(12). Available from: http://dx.doi.org/10.1038/s12276-018-0194-y
  • La Sala L, Mrakic-Sposta S, Tagliabue E, Prattichizzo F, Micheloni S, Sangalli E, et al. Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naïve T2D. Cardiovasc Diabetol [Internet]. 2019;18(1):1–12. Available from: https://doi.org/10.1186/s12933-019-0824-2
  • Ghai V, Baxter D, Wu X, Kim TK, Kuusisto J, Laakso M, et al. Circulating RNAs as predictive markers for the progression of type 2 diabetes. J Cell Mol Med. 2019;23(4):2753–68.
  • Feng T, Li K, Zheng P, Wang Y, Lv Y, Shen L, et al. Weighted Gene Coexpression Network Analysis Identified MicroRNA Coexpression Modules and Related Pathways in Type 2 Diabetes Mellitus. Oxid Med Cell Longev. 2019;2019.
  • Ghoreishi E, Shahrokhi SZ, Kazerouni F, Rahimipour A. can be potential biomarkers for diagnosis of pre ‑ diabetes and type 2 diabetes : integrating experimental and in ‑ silico approaches. BMC Endocr Disord [Internet]. 2022;1–10. Available from: https://doi.org/10.1186/s12902-022-01120-5
  • Ramanjaneya M, Priyanka R, Bensila M, Jerobin J, Pawar K, Sathyapalan T, et al. MiRNA and associated inflammatory changes from baseline to hypoglycemia in type 2 diabetes. Front Endocrinol (Lausanne). 2022;13(August):1–10.
  • Zeinali F, Zarch SMA, Jahan-Mihan A, Kalantar SM, Mehrjardi MYV, Fallahzadeh H, et al. Circulating microRNA-122, microRNA-126-3p and microRNA-146a are associated with inflammation in patients with pre-diabetes and type 2 diabetes mellitus: A case control study. PLoS One [Internet]. 2021;16(6 6):1–13. Available from: http://dx.doi.org/10.1371/journal.pone.0251697
  • Yazdanpanah Z, Kazemipour N, Kalantar SM, Vahidi Mehrjardi MY. Plasma miR-21 as a potential predictor in prediabetic individuals with a positive family history of type 2 diabetes mellitus. Physiol Rep. 2022;10(2):1–9.
  • Monfared YK, Honardoost M, Sarookhani MR, Farzam SA. Circulating miR-135 May Serve as a Novel Co-biomarker of HbA1c in Type 2 Diabetes. Appl Biochem Biotechnol. 2020;191(2):623–30.
Data source: Dialnet